Metastatic bone disease arises when malignant cells colonise the bone microenvironment, disrupting the balanced activities of bone‐resorbing osteoclasts and bone‐forming osteoblasts. Tumour cells ...

SUZETRIGINE showed limited benefit for cancer-related bone pain in three patients with metastatic spinal disease.

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior ...

Investigators evaluated a response-based radiotherapy approach for pediatric patients with metastatic rhabdomyosarcoma.

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...